TY - JOUR
T1 - Expression of LAT1 and 4F2hc in gastroenteropancreatic neuroendocrine neoplasms
AU - Horita, Yosuke
AU - Kaira, Kyoichi
AU - Kawasaki, Tomonori
AU - Mihara, Yoshiaki
AU - Sakuramoto, Shinichi
AU - Yamaguchi, Shigeki
AU - Okamoto, Kojun
AU - Ryozawa, Shomei
AU - Kanai, Yoshikatsu
AU - Yasuda, Masanori
AU - Hamaguchi, Tetsuya
N1 - Publisher Copyright:
© 2021 International Institute of Anticancer Research. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - Background/Aim: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. Patients and Methods: Tissues from 126 patients with GEP-NENs were collected between August 2007 and August 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. Results: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). Conclusion: No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident.
AB - Background/Aim: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. Patients and Methods: Tissues from 126 patients with GEP-NENs were collected between August 2007 and August 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. Results: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). Conclusion: No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident.
KW - 4F2hc
KW - Amino acid transporter
KW - CD98
KW - Gastroenterology
KW - LAT1
KW - Neuroendocrine tumour
UR - https://www.scopus.com/pages/publications/85109065503
UR - https://www.scopus.com/inward/citedby.url?scp=85109065503&partnerID=8YFLogxK
U2 - 10.21873/INVIVO.12520
DO - 10.21873/INVIVO.12520
M3 - Article
C2 - 34182526
AN - SCOPUS:85109065503
SN - 0258-851X
VL - 35
SP - 2425
EP - 2432
JO - In Vivo
JF - In Vivo
IS - 4
ER -
